Ruxolitinib, a first‐generation JAK1/2 inhibitor, has demonstrated limited efficacy in CMML, with current clinical research indicating an overall response rate of merely 35%.[56] Our study pioneers the therapeutic potential of Baricitinib, a second‐generation selective JAK inhibitor, for CMML. This evidence concerns the gene JAK1 and chronic myelomonocytic leukemia.